[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Case Comprehensive Cancer Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":602},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,60,0,25,[9,45,72,98,119,142,166,192,214,235,257,279,302,327,356,377,404,428,451,476,499,517,540,561,580],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100527642","phase-2-mdrt-in-prostate-cancer-treated-with-long-term-androgen-deprivation-therapy-in-the-stampede-trial-metanova-100527642",false,"NCT06150417","MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)","Metastasis-directed Radiotherapy (MDRT) for Men With De-novo Oligometastatic Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)","Inclusion Criteria:\n\n* Participant must be ≥ 18 years of age.\n* Participant must have an ECOG performance status ≤ 1.\n* Histologic confirmation of prostate adenocarcinoma of the prostate gland, with evidence of metastasis on imaging by conventional imaging (MRI, CT, or 99mTc bone scan) or PSMA PET\u002FCT. Biopsy of sites of metastasis is strongly encouraged, but not required.\n\n  * There must be at least 10-15 unstained slides from 2 cores of the highest tumor cellularity available.\n* Newly diagnosed disease with no prior treatment(surgery, radiation or systemic treatment, ie hormone therapy or chemotherapy) to the primary disease.\n\n  * Participants may have started LHRH agonist or antagonist therapy, and\u002For androgen receptor signaling inhibitor (ARSI) as long as it was not started more than 30 days before the participant is enrolled on this study.\n* In participants who undergo only conventional imaging, oligometastatic disease is defined as 1-5 discrete metastatic sites in the bone and\u002For extra-pelvic lymph node (LN) stations.\n\n  * Extra-pelvic LN stations are superior to the regional\u002Fpelvic LN stations. Pelvic LN stations commence at the bifurcation of the aorta and bifurcation of the proximal inferior vena cava to the common iliac veins.\n\n    * Radiographic criteria for a LN to be considered a metastatic focus is defined as short-axis diameter in the axial plane of ≥ 1.0 cm, with irregular border and\u002For heterogeneous morphology\n* In participants who undergo PSMA PET\u002FCT (in the presence or absence of conventional imaging), oligometastatic disease is defined as 1-10 PSMA avid bone lesions and\u002For extra-pelvic LN stations. The MI-RADS reporting system will be followed to guide PSMA PET interpretation\n\n  * In participants extra-pelvic nodal (M1a) disease only by PSMA PET\u002FCT and M0 by conventional imaging (i.e. extra-pelvic LN did not meet size criteria by CT), participant must meet 2 of 3 following criteria in order to be eligible:\n\n    * 1\\. PSA ≥ 40\n    * 2\\. Evidence of cN1 disease (pelvic LN)\n    * 3\\. Decipher score ≥ 0.89\n* Adequate organ and marrow function to receive treatment per treating physician\n* Medically fit for treatment and agreeable to follow-up.\n* Ability to understand and the willingness to sign a written informed consent.\n\nExclusion Criteria:\n\nParticipants with the presence of any of the following:\n\n* Castration resistant prostate cancer (CRPC).\n* Evidence of visceral or intracranial metastases.\n* Participant receiving any other investigational agents for cancer.\n* Participant is participating in a concurrent treatment protocol for cancer.\n* Unable to lie flat during or tolerate PET\u002FMRI, PET\u002FCT or SBRT.\n* Prior definitive treatment to the primary prostate cancer or pelvis.\n* Participant with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, uncontrolled diabetes (HgA1c \\> 10), active pituitary or adrenal dysfunction, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* History of another active malignancy within the previous 2 years, except for non-melanoma skin cancer, non-muscle invasive bladder cancer, or a malignancy that is considered cured with minimal risk of recurrence\n* Active Crohn's disease or ulcerative colitis despite medical management.\n* Refusal to sign informed consent.\n* Any condition that in the opinion of the investigator would preclude participation in this study","MALE","18 Years",{"count":20,"type":21},200,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The purpose of this study is to find out if giving radiation therapy (RT) to areas of metastatic prostate cancer at the time a participant is diagnosed will help control disease better than the usual treatment. This treatment is called metastasis-directed radiotherapy (MDRT).\n\nThe usual treatment for prostate cancer that has spread to other parts of the body is to give lifelong treatment with hormone therapy (also known as androgen deprivation therapy or ADT). Participants may also be given prostate RT even if the disease is metastatic. Participants will receive hormone therapy (the standard treatment for prostate cancer) for 12 months. The hormone therapy agents may be taken by mouth or given as an injection. Participants will also have prostate RT. Up to 50 participants will have surgery to remove the prostate instead of having prostate RT. A portion of the participants will be randomized to receive MDRT to areas where the cancer has spread. For participants who have surgery to remove their prostate, they will be asked to allow tissue samples collected during the surgery to be sent to an outside lab for research tests and extra blood samples drawn for research tests before starting the study, and at the time the cancer becomes worse if applicable. Participation in the study will last approximately 12 months, and will be followed by their doctor for up to five years per standard of care.\n\nThe main goal is to compare the efficacy of the standard of care (standard systemic therapy + definitive prostate-directed local therapy) versus the standard of care with metastasis-directed radiotherapy (MDRT) for consolidation of metastatic disease.",[27,28,29],"Prostate Cancer","Malignant Neoplasm of Prostate","Secondary Malignant Neoplasm of Prostate",[31],"Metastasis-directed Radiotherapy","RECRUITING","2026-06-30",{"date":35,"type":36},"2026-07-01","ACTUAL",{"date":38,"type":36},"2024-07-01",{"date":40,"type":21},"2028-12-01",{"name":42,"class":43},"Case Comprehensive Cancer Center","OTHER",2,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},"100601755","fatty-acid-binding-proteins-and-markers-of-cellular-senescence-in-cancer-survivors-100601755","NCT07114614","Fatty Acid Binding Proteins and Markers of Cellular Senescence in Cancer Survivors","Inclusion Criteria:\n\n* Diagnosis of at least one malignancy for which chemotherapy, radiation, and\u002For stem cell transplantation was utilized as part of treatment\n* Completed all therapeutic interventions for their malignancy and are at least 2 years off therapy\n* At least 1-year post-stem cell transplant for malignant condition\n\nExclusion Criteria:\n\n1. Pregnancy at the time of the study\n2. Any autoimmune condition including but not limited to lupus, rheumatoid arthritis, Crohn's disease, ulcerative colitis, type 1 diabetes, EXCEPT well-controlled autoimmune hypothyroidism for at least 6 months\n3. Presence of active graft versus host disease\n4. Malignancy treated using surgery only\n5. Acute relapsed disease or second malignancy\n6. Transplant for non-malignant conditions (e.g. cell disease, Hurler syndrome)\n7. Currently taking systemic steroids and\u002For immunosuppressant medications\n8. Acute illness necessitating hospitalization in the 30 days prior to blood draw\n9. Presence of a chronic inflammatory disease EXCEPT obesity\n10. Fever, active infection or inflammation, or taking antibiotics at the time of blood draw\n11. A diagnosis of Type 2 diabetes or Hypertension treated with medication\n12. Currently lipid lowering medications\n13. Growth hormone deficiency or hypothalamic dysfunction","ALL","5 Years","50 Years",{"count":55,"type":21},120,"OBSERVATIONAL","The purpose of this research study is to investigate whether cancer survivors have higher levels of proteins called Fatty Acid Binding Proteins as well as 12 different markers of cellular senescence than people who have never had cancer. Investigators believe that these levels may be elevated in cancer survivors as a result of their cancer and the treatments they received and may put them at higher risk for chronic conditions such as high cholesterol, diabetes, high blood pressure, and obesity. This study will also compare the levels of these proteins and inflammatory markers in the blood with different aspects of cancer treatment the survivors received. Investigators are investigating if there is a correlation between levels of these proteins and markers, the type of treatment cancer survivors received, and development of metabolic conditions.",[59],"Marker; Structural",[61,62,63],"Fatty Acid Binding Proteins","Cancer Survivors","FABP4 and FABP5","2026-06-29",{"date":35,"type":36},{"date":67,"type":21},"2026-07",{"date":69,"type":21},"2026-12",{"name":42,"class":43},1,{"id":73,"slug":74,"hasResults":12,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":12,"sex":51,"minAge":79,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":92,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":71},"100494995","transplantation-of-reconstructed-renal-allografts-following-ex-vivo-partial-nephrectomy-100494995","NCT05725421","Transplantation of Reconstructed Renal Allografts Following Ex-Vivo Partial Nephrectomy","Oncologic, Functional and Surgical Outcomes for Patients Undergoing Radical Nephrectomy for Low-Risk Renal Cell Carcinoma and Recipients of Reconstructed Renal Allografts Following Ex-Vivo Partial Nephrectomy","Inclusion Criteria:\n\nFor Donors:\n\n* Adults \\> 50 years\n* Willing and able to understand and sign informed consent\n* Must have high-quality pre-operative cross-sectional imaging (CT or MRI) to determine tumor characteristics and perform parenchymal volume analysis for split renal function\n* Patient who is a candidate for partial nephrectomy for cT1a mass who understands that partial nephrectomy is standard of care for such mass but wishes to be an altruistic kidney donor (primary incentive is altruism) via radical nephrectomy with loss of the entire kidney.\n* Functional considerations:\n\n  o Normal baseline renal function, with eGFR \\> 80 ml\u002Fmin\u002F1.73 m2\n  * No proteinuria on urine dipstick (negative\u002Ftrace considered negative)\n  * Predicted new baseline GFR (NBGFR) following radical nephrectomy would be ≥ 45\n  * NBGFR would be calculated using previously described equation based on split renal function (SFR) and renal functional compensation (RFC)\n  * NBGFR = global GFR x (SRFcontralateral from PVA) x 1.25 (average amount of RFC)2\n* Tumor characteristics on pre-operative cross-sectional imaging:\n\n  * Tumor appears well-encapsulated\n  * Tumor appears amenable to ex-vivo partial nephrectomy with reconstruction that will leave ≥75% of the functioning parenchyma intact and well vascularized\n  * Low risk of complications for the recipient after ex-vivo PN based on surgeon judgment\n  * Tumor is cT1a which is defined as ≤ 4cm and confined\n  * Reconstructed kidney is likely to provide NBGFR for the recipient of \\>30 ml\u002Fmin\u002F1.73 m2. This can be estimated as (global GFR)(SRFipsilateral) x 0.75(estimate that at least 75% of the function will be saved during ex vivo tumor excision and reconstruction). Of note most such kidneys will experience some positive functional compensation but this might be mitigated by a small amount of functional loss related to ischemia. Most studies suggest that this will really be an underestimate of the final GFR in the recipient.\n\nFor Recipients:\n\n* Age \\>60\n* Able to understand and willing to sign informed consent\n* Presence of ESRD or CKD5 with likely progression to ESRD\n* Does not have potential living donor\n* Not likely to receive a more \"ideal\" donor kidney due to significant comorbidities and\u002For age\n\nExclusion Criteria:\n\nFor Donors:\n\n* Known familial RCC syndrome\n* Functional considerations:\n\n  o \\\u003C 50 years of age\n  * Preoperative GFR \\\u003C 80 ml\u002Fmin\u002F1.73 m2\n  * Proteinuria on urine dipstick or urinalysis (≥1+ considered positive)\n  * Predicted new baseline GFR (NBGFR) following radical nephrectomy would be \\\u003C 45\n  * NBGFR would be calculated using previously described equation based on split renal function (SFR) and renal functional compensation (RFC)\n  * NBGFR = global GFR x (SRFcontralateral from PVA) x 1.25 (average amount of RFC)2\n* Comorbidities with risk of deteriorating renal function:\n\n  * Hypertension requiring three or more anti-hypertensives\n  * Diabetes mellitus requiring insulin or with end organ damage\n  * Morbid obesity\n  * History of nephrolithiasis or other\n* Tumor characteristics on pre-operative cross-sectional imaging:\n\n  o Tumor has infiltrative features\n  * Tumor is \\> 4cm (does not meet criteria for cT1a stage)\n  * Regional lymphadenopathy, branch or main renal vein invasion, or other imaging findings suggestive of locally advanced disease\n* Kidney characteristics on pre-operative cross-sectional imaging:\n\n  * More than one renal artery unless can be readily and safely reconstructed\n  * More than one renal vein unless can be readily and safely reconstructed\n  * Duplicated collecting system unless can be readily and safely reconstructed\n* High-risk features on renal mass biopsy (if obtained) or intraoperative pathology\n\n  o Malignant non-RCC pathology\n\n  o Rhabdoid or sarcomatoid differentiation\n\n  o Grade 4\n\n  o Positive or concerning margins during tumor excision\n* Must be deemed appropriate living donor candidate per the standard living donor selection process at the Cleveland Clinic o All altruistic living donors undergo a complete evaluation by medical providers and social workers ensuring that they are appropriate candidates to undergo this procedure. This evaluation includes direct query into any history of psychiatric comorbidities and\u002For substance abuse. If present, this prompts a formal evaluation by psychiatry prior to confirmation of donor candidacy.\n\nFor Recipients:\n\n• Traditional contraindications to kidney transplantation at the Cleveland Clinic would apply, including the following directly from the Transplant Care Pathway:\n\n* Active, untreated bacterial, fungal, or viral infections. Once treated, patients may be reconsidered. Patients with human immunodeficiency virus (HIV)14 or chronic hepatitis15 infections will be evaluated on an individual basis.\n* Active malignancy, except non-melanoma skin cancer and other selected low-grade, low-stage cancers (e.g., bladder, kidney, prostate). The American Society of Transplant (AST) clinical practice guidelines published in 2001 are dated. Improved methods of cancer prognostication are available on a cancer-specific basis.16 An acceptable disease-free waiting period may be needed prior to transplantation depending on the cancer type (stage\u002Fgrade) and treatment modality. Expert opinion from an oncological specialist may be needed to facilitate decisions about wait-listing or performance of a transplant.\n* Medical non-adherence, substance abuse or behaviors leading to a failure to achieve a therapeutic physician\u002Ftransplant team-patient alliance.\n* Life expectancy of less than five years independent of renal disease.\n* Advanced circulatory disease (cardiac, cerebral, peripheral), pulmonary disease or other non-renal conditions such that transplantation would pose a significant risk for morbidity\u002Fmortality.\n* Obesity with body mass index (BMI) \\> 38, or an abdominal wall configuration that in the judgment of the evaluating surgeon poses undue complication risk.\n* Active nicotine abuse (in any form).\n* Poor functional status independent of renal disease.\n* Considering the average waiting times for a deceased donor kidney is more than 3 years, only transplant candidates 72 years or younger will be accepted for evaluation. Suitable candidates may remain on the waiting list up to the age of 75-year-old. They will be delisted if no transplantation has occurred.\n* Cumulative burden of disease defined as multiple medical conditions that on their own may not preclude listing but that in combination are deemed not suitable by the transplant selection committee.","60 Years",{"count":81,"type":21},5,[83],"NA","This study is designed to investigate a novel approach to offer more ESRD participants the benefits associated with renal transplantation by increasing the supply of available allografts",[86],"Renal Cell Carcinoma",[88,89,90],"Radical Nephrectomy","Renal Allograft","Ex-Vivo Partial Nephrectomy","NOT_YET_RECRUITING",{"date":33,"type":36},{"date":94,"type":21},"2026-08",{"date":96,"type":21},"2027-06",{"name":42,"class":43},{"id":99,"slug":100,"hasResults":12,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":12,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":44},"100200880","phase-1-neoadjuvant-radiosurgery-for-resectable-brain-metastases-phase-iii-study-100200880","NCT01891318","Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I\u002FII Study","Inclusion Criteria:\n\n* Have a prior histologic diagnosis of cancer other than small cell lung cancer, lymphoma, and germ cell histologies\n* Magnetic resonance imaging (MRI) evidence of 1-4 brain metastases, with at least one lesion \\> 20 mm and ≤ 50 mm in maximal diameter and determined to be appropriate for SRS and gross total resection; all other brain metastases are appropriate for SRS\n* Patient can have prior SRS to lesions other than the one planned for neoadjuvant SRS and resection\n* Patient must have a Karnofsky performance score of ≥ 70\n\nExclusion Criteria:\n\n* Patient deemed medically unfit to undergo surgical resection of brain metastasis\n* Prior whole brain radiotherapy\n* Patient with contraindication for imaging with MRI\n* Inability to participate in study activities due to physical or mental limitations\n* Inability or unwillingness to return for all the required follow-up visits\n* At the time of planning, unable to deliver 10 Gray (Gy) or less to optic nerve\u002Fchiasm\n* Tumor located in the brainstem\n* Imaging or cytologic evidence of leptomeningeal disease",{"count":105,"type":21},36,[107,24],"PHASE1","This Phase I\u002FII trial studies the ability to stop brain metastases from coming back after treatment with radiosurgery followed by surgical resection. It will also evaluate the side effects of these combined treatments and help determine the best radiosurgery dose. Radiosurgery focuses the x-rays directly to the tumor and cause less damage to the normal tissue in the brain.",[110],"Tumors Metastatic to Brain","2026-06-25",{"date":113,"type":36},"2026-06-26",{"date":115,"type":36},"2013-07-03",{"date":117,"type":21},"2026-09",{"name":42,"class":43},{"id":120,"slug":121,"hasResults":12,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":12,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":22,"phases":128,"briefSummary":129,"conditions":130,"keywords":133,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":71},"100593215","phase-2-a-phase-2-and-pharmacodynamic-study-of-sitagliptin-in-patients-with-progressive-grade-4-gliomas-100593215","NCT07003542","A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas","Targeting Macrophage Migration Inhibitory Factor: A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas","Inclusion Criteria:\n\n1. Participants must have histologically or cytologically confirmed WHO grade 4 glioma (including tumors with molecularly defined grade 4 astrocytoma) for whom a clinically-indicated tumor resection is planned.\n2. Participants must not have received sitagliptin or other gliptins.\n3. Participants must, in the opinion of the investigator be able to tolerate a pre-operative dexamethasone dose of 4 mg\u002Fd or the equivalent dose of an alternate glucocorticoid.\n4. Age \\>18 years\n5. Karnofsky performance status ≥ 60%\n6. Participants must have adequate organ function and laboratory parameters within 21 days of study entry as defined below:\n\n   * Hemoglobin ≥ 9 g\u002Fdl\n   * Absolute neutrophil count ≥ 1,500\u002FmcL\n   * Platelet count ≥ 100,000\u002FmcL\n   * Total bilirubin \\\u003C 1.5x institutional upper limit of normal (ULN)\n   * AST (SGOT) ≤ 3x institutional ULN\n   * ALT (SGPT) ≤ 3x institutional ULN\n   * Calculated creatinine clearance \\> 50 mL\u002Fmin or creatinine \\\u003C 1.5x institutional upper limit of normal (ULN)\n   * Prothrombin time\u002Finternational normalized ratio (PT\u002FINR) \\\u003C 1.4 for participants not on warfarin.\n7. Participants on full-dose anticoagulants (e.g., warfarin or LMW heparin) must meet both of the following criteria:\n\n   * No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices)\n   * In-range INR (between 2 and 3) on a stable dose of oral anticoagulant or on a stable dose of low molecular weight heparin.\n8. Women of childbearing potential must have a negative pregnancy test within 21 days of study entry. Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and through 30 days after the last dose of study drug. Should a woman become pregnant or suspect she is pregnant while taking part in this study, she should inform her treating physician immediately. Men of reproductive potential treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and through 30 days after the last dose of study drug.\n9. Participants must be able to swallow whole tablets.\n10. Participants must have the following minimum intervals from prior treatments:\n\n    * surgery - 4 weeks\n    * nitrosoureas - 6 weeks\n    * cytotoxic chemotherapy - standard intervals depending on the most recent regimen. E.g., for temozolomide 23 days after most recent dose.\n    * For drugs not listed, the research nurse, treating investigator, and principal investigator will decide on the appropriate interval.\n    * Investigational therapy or non-cytotoxic therapy - 2 weeks.\n    * For bevacizumab - 4 weeks from expected date of protocol surgery\n11. Participants positive for human immunodeficiency virus (HIV) are allowed on study (note: HIV testing is not required), but HIV-positive participants must have:\n\n    * An undetectable viral load within 6 months of registration.\n    * A stable regimen of highly active anti-retroviral therapy (HAART)\n    * No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\n12. For participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load Note: Known positive test for HCV ribonucleic acid (HCV RNA) indicating acute or chronic infection would make the patient ineligible unless the viral load becomes undetectable on suppressive therapy.\n13. For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.\n\n    Note: A known positive test for HBV surface antigen (HBV sAg) indicating acute or chronic infection would make the patient ineligible unless the viral load becomes undetectable on suppressive therapy. Participants who are immune to hepatitis B (anti-Hepatitis B surface antibody positive) are eligible (e.g., participants immunized against hepatitis B)\n14. Patient must be deemed by investigator to be a candidate for post-operative chemotherapy.\n15. Participants must have the ability to understand and the willingness to sign a written informed consent document.\n\n    Exclusion Criteria:\n16. Prior treatment toxicities not resolved to ≤ Grade 1 according to NCI CTCAE Version 5.0 except alopecia and neuropathy.\n17. Participants receiving any other investigational agents.\n18. History of allergic reactions attributed to compounds of similar chemical or biologic composition to sitagliptin.\n19. Participants with uncontrolled diabetes mellitus\n20. Participants who require insulin therapy or a sulfonylurea\n21. Participants with documented history of hypoglycemia requiring medical intervention or who in the opinion of the investigator are not suitable to receive sitagliptin.\n22. Participants with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n23. Other prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen are excluded. Otherwise, participants with prior or concurrent malignancy are eligible.\n24. Significant chronic gastrointestinal disorder with diarrhea as a major symptom (e.g., Crohn's disease, malabsorption, or Grade ≥2 diarrhea of any etiology at screening) (National Cancer Institute \\[NCI\\] Common Terminology Criteria for Adverse Events Version 5.0 \\[CTCAE v.5.0\\]).\n25. Pregnant or breastfeeding.\n26. Unable or unwilling to swallow tablets.\n27. Evidence of significant medical illness, abnormal laboratory finding, or psychiatric illness\u002Fsocial situations that would, in the investigator's judgment, make the patient inappropriate for this study.",{"count":127,"type":21},48,[24],"The purpose of this study is to evaluate whether treating glioblastoma patients with sitagliptin can improve immune response against the tumor by targeting specific immune cells called myeloid-derived suppressor cells (MDSCs) that suppress your body's natural immune response against cancer.\n\nSitagliptin is an investigational drug for this condition that works by inhibiting an enzyme called dipeptidyl peptidase 4 (DPP-4), which MDSCs rely on to enter the brain and function. While sitagliptin is FDA-approved for diabetes treatment, its use in glioblastoma is investigational (experimental).",[131,132],"Glioblastoma","Brain Tumor",[134],"Myeloid-derived suppressor cells","2026-06-24",{"date":111,"type":36},{"date":138,"type":36},"2026-03-16",{"date":140,"type":21},"2028-06",{"name":42,"class":43},{"id":143,"slug":144,"hasResults":12,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":12,"sex":149,"minAge":18,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":22,"phases":152,"briefSummary":153,"conditions":154,"keywords":156,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":161,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":165,"locationsCount":71},"100545820","fasting-during-neoadjuvant-chemotherapy-in-patient-with-epithelial-ovarian-cancer-100545820","NCT06386887","Fasting During Neoadjuvant Chemotherapy in Patient With Epithelial Ovarian Cancer","The Feasibility, Safety, and Clinical Outcomes of Fasting During Neoadjuvant Chemotherapy in Patients With Epithelial Ovarian Cancer","Inclusion Criteria:\n\n* Age 18 years and above\n* Participants with confirmed diagnosis of primary epithelial ovarian cancer (EOC) by internal cytologic or histologic evaluation (including fallopian tube and primary peritoneal cancer)\n* Participants receiving platinum-based chemotherapy for ovarian cancer including\n\n  * Participants with stage III or IV EOC planned to undergo neoadjuvant chemotherapy (including participants who had a diagnostic laparoscopy or aborted debulking) OR\n  * Participants with stage III or IV EOC following primary debulking surgery\n  * Participants with recurrent epithelial ovarian cancer who will receive platinum-based chemotherapy OR\n  * Participants who had undergone neoadjuvant chemotherapy and interval debulking surgery who will be receiving adjuvant (postoperative) chemotherapy\n* Any invasive ovarian cancer histology\n* Normal cognitive function\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Malignant complete or partial bowel obstruction confirmed on imaging.\n* Participants unable to provide informed consent.\n* BMI \\\u003C18\n* Participants diagnosed with severe malnutrition as assessed by study dietitian\n* Type I diabetes on insulin\n* Absence of pretreatment CT abdomen and pelvis imaging or \\>4-6 weeks between imaging and cycle 1 of chemotherapy.","FEMALE",{"count":151,"type":21},20,[83],"The goal of this clinical trial is to see if timed fasting (periods of time that you don't eat) in participants who are receiving chemotherapy prior to surgery is achievable, safe and can improve quality of life, symptoms and outcomes (results) compared to participants who receive standard dietary recommendations in individuals being treated for epithelial ovarian cancer . The main questions it aims to answer are:\n\n* Is it feasible to use intermittent fasting during neoadjuvant chemotherapy?\n* Is it safe to use intermittent fasting during neoadjuvant chemotherapy?\n* Do participants find it acceptable to use intermittent fasting during neoadjuvant chemotherapy?\n\nResearchers will compare participants who receive standard dietary recommendations to see which method is more achievable, safe, and able to improve quality of life, symptoms and outcomes.\n\nParticipants will:\n\n* Receive either the fasting intervention (schedule of times when you do not eat) or standard diet recommendations for 6-9 weeks prior to your surgery starting with the second cycle of chemotherapy.\n* All participants will be asked to complete chemotherapy and surgery, cancer imaging, baseline screening tests, nutritional assessments, food diaries, blood tests, and surveys about wellbeing.\n* Participants in the intervention group will be asked to follow a fasting schedule that consists of not eating for 16 hours a day followed by normal eating for the remaining 8 hours of the day for 5 days in a row followed by 2 days of regular eating each week.",[155],"Epithelial Ovarian Cancer",[157,158,159,160],"Short term fasting","Intermittent fasting","Intermittent energy restriction (IER)","Fasting mimicking diet (FMD)",{"date":111,"type":36},{"date":163,"type":36},"2024-07-11",{"date":35,"type":21},{"name":42,"class":43},{"id":167,"slug":168,"hasResults":12,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":12,"sex":51,"minAge":173,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":22,"phases":176,"briefSummary":177,"conditions":178,"keywords":181,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":186,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":44},"100526054","phase-2-repeat-breast-conserving-surgery-followed-by-daily-partial-breast-irradiation-in-ipsilateral-breast-100526054","NCT06129747","Repeat Breast Conserving Surgery Followed by Daily Partial Breast Irradiation in Ipsilateral Breast","Repeat Breast Conserving Surgery Followed by Daily Partial Breast Irradiation for Participants With Ipsilateral Breast Tumor Recurrence Treated Initially With Breast Conserving Surgery and Whole Breast Radiation Therapy","Inclusion Criteria:\n\n* Participants' recurrences must have histologically confirmed ductal carcinoma in-situ, invasive ductal, medullary, papillary, colloid (mucinous), tubular or mixed histologies. Three years of time must have elapsed since the end of the last course of whole breast irradiation.\n* Lesion size \\\u003C 3 cm treated with a partial mastectomy. Participants with invasive cancer and clinically and radiographically negative axillas do not require an axillary lymph node sampling unless they did not have prior axillary lymph node sampling (e.g. previous cancer was DCIS). Participants with DCIS as their recurrence do not require surgical assessment of the axilla. Repeat sentinel lymph node biopsy is permitted.\n* Negative resection margins with at least no tumor on ink or a negative re-excision.\n* Participants with invasive recurrence must have a negative re-staging work-up consisting of either a CT chest\u002Fabdomen and a bone scan or a PET scan.\n* Hormonal therapy is allowed. If chemotherapy is planned, it can be delivered either prior to or after the radiation is delivered. There must be at least 2 weeks between radiation and chemotherapy. HER2 directed therapy can be delivered concurrently with radiation.\n* Participants must be \\> 18 years of age. Because no dosing or adverse event data are currently available on the use of breast re-irradiation in participants ≤18 years of age, children are excluded from this study.\n* Participants must have the ability to understand and the willingness to sign a written informed consent document.\n* Performance status: ECOG Performance status ≤ 2.\n* Life expectancy of ≥ 12months, in the opinion of and as documented by the investigator.\n* Not based on gender; this trial is open to any gender, defined as self-representation of gender identity.\n\nExclusion Criteria:\n\n* Participants with nodal or distant metastatic disease \\\u003C 3 years since prior radiation.\n* Participants with invasive pure lobular carcinoma, extensive lobular carcinoma in-situ, extensive ductal carcinoma in-situ (spanning more than 3 cm), or uncontrolled nonepithelial breast malignancies such as lymphoma or sarcoma.\n* Participants with multicentric carcinoma (tumors in different quadrants of the breast or tumors separated by at least 4 cm). Palpable or radiographically suspicious contralateral axillary, ipsilateral or contralateral supraclavicular, infraclavicular, or internal mammary lymph nodes unless these are histologically or cytologically confirmed negative.\n* Participants with Paget's disease of the nipple.\n* Participants with skin involvement.\n* Participants with scleroderma or dermatomyositis.\n* Participants with psychiatric, neurologic, or addictive disorders that would preclude obtaining informed consent.\n* Participants who are pregnant or lactating due to potential fetal exposure to radiation and unknown effects of radiation on lactating females.\n* Participants with known BRCA 1\u002FBRCA 2 mutations.","19 Years",{"count":175,"type":21},55,[24],"The standard treatment for participants whose cancer has returned after breast conserving surgery is radiation given twice daily (separated by at least 6 hours) for a total of 30 treatments. The purpose of this study is to find out if giving radiation once a day for 15 treatments after repeat breast conserving surgery works as well as giving it the standard way.",[179,180],"Breast Cancer","Tumor, Breast",[182,183,184,185],"Radiation Therapy","In-Breast Recurrence","Tumor","Re-irradiation",{"date":111,"type":36},{"date":188,"type":36},"2023-11-30",{"date":190,"type":21},"2029-08-09",{"name":42,"class":43},{"id":193,"slug":194,"hasResults":12,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":4,"eligibilityCriteria":198,"healthyVolunteers":12,"sex":17,"minAge":173,"maxAge":4,"enrollmentInfo":199,"targetDuration":4,"studyType":22,"phases":201,"briefSummary":202,"conditions":203,"keywords":205,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":208,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":71},"100486190","single-port-transvesical-partial-prostatectomy-versus-high-intensity-focused-ultrasound-100486190","NCT05610852","Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound","Prospective Single-Center Randomized Study Of Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound (HIFU)","Inclusion Criteria:\n\n* Subjects must have histologically or cytologically: Biopsy-confirmed prostate cancer, stage T1a, T2a, T2b, or T2c prostate cancer using MRI staging, with a region of interest (ROI) PIRADs grade 3 or greater, Serum PSA 10 ng\u002Fml or less, Region of interest on MRI of grade 3 or greater\n* The MRI performed must include at least:\n* A T2-weighted sequence in sections ≤ 4 mm, centered on the prostate and seminal vesicles, at least in the axial plane. Alternatively, a 3D T2-weighted sequence can be realized,\n* A diffusion sequence of ≤ 4 mm slice in the axial plane. An ADC card will be provided and calculated from at least two values of b, the maximum value of b being ≥ 600 s \u002F mm2,\n* A dynamic sequence after gadolinium injection. It will be a sequence of echo T1-weighted gradient of slice ≤ 4 mm, centered on the prostate and seminal vesicles in the axial plane, with or without fat saturation. A first series will be performed without contrast injection, and will be repeated iteratively for the arrival of a bolus of gadolinium chelates. The time resolution (that is to say, the acquisition time of one dynamic series will be ≤ 20 seconds). The number of chained dynamic series is calculated so that the total length of the dynamic acquisition be at least 3 minutes\n* A total dose of 0.1 mmol \u002F kg of gadolinium chelate will be injected at a rate of 3-4 mL \u002F s by using an automatic injector, in a vein of the hand of the forearm or elbow.\n* If necessary, subtracted images are calculated\n* Clinically significant prostate cancer defined as Gleason score 3+4 or less in any core\n* Biopsies for preoperative diagnosis of prostate cancer will have included: At least 12 randomized samples (2 samples per sextant), At least two targeted sampling on each target score MRI ESUR ≥ 3\u002F5\n* Life expectancy greater than 10 years.\n* Age \\>18 years.\n* Subjects must have the ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Patients with any prior extensive pelvic surgery, pelvic fractures, hemorrhoid, fissure surgery, cardiac pacemaker, or metal prosthesis\n* Prior treatment for prostate cancer such as radiotherapy, focal or hormonal therapy\n* Uncorrected coagulopathy or history of Latex allergy\n* Active soft tissue or urinary infection, indwelling Foley catheter or severe irritative or obstructive symptoms\n* Poor surgical risk (defined as American Society of Anesthesiology score \\> 3).\n* Any condition or history of illness or surgery that, in the opinion of the investigator, might confound the results of the study or pose additional risk to the patient (e.g. significant cardiovascular conditions that significantly affect the life expectancy, chronic opiate use, pain syndrome, or drug abuse.)\n* Prostate size larger than 80 grams.\n* Subjects with prostatic Calcification (\\>0.5 cc) close to the area to be treated.\n* Subjects with extraprostatic extension or cribriform pattern on biopsy.\n* Subjectes with sexual dysfunction defined as SHIM score \\\u003C 17\n* Subjects with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.",{"count":200,"type":21},276,[83],"This study aims to compare the novel single-port robotic partial prostatectomy to High-intensity focused ultrasound (HIFU) in patients with low to intermediate risk localized prostate cancer. These interventions have become acceptable focal therapies prevalent with beneficial oncologic outcomes and therefore need to be examined further.",[204,27],"Prostate Adenocarcinoma",[206,207],"High Intensity Focused Ultrasound (HIFU)","Single-Port Transvesical Partial Prostatectomy",{"date":111,"type":36},{"date":210,"type":36},"2024-01-01",{"date":212,"type":21},"2028-07-01",{"name":42,"class":43},{"id":215,"slug":216,"hasResults":12,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":12,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":22,"phases":223,"briefSummary":224,"conditions":225,"keywords":227,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":230,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":234,"locationsCount":71},"100482675","phase-1-prospective-surgical-study-on-the-pattern-of-electrical-activity-in-high-grade-glioma-as-a-predictor-of-progression-100482675","NCT05565118","Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma as a Predictor of Progression","Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma (WHO Grade III and IV) as a Predictor of Progression","Inclusion Criteria:\n\n* Participants who have the appearance of high-grade glioma (HGG, WHO Grade 3 and 4, including GBM) on MR imaging are allowed to consent and will undergo the procedure if the frozen is consistent with HGG\n\nOR\n\n* Participants with a history of histologically-confirmed diagnosis of high- grade glioma that are undergoing resection of a recurrent\u002Fprogressive tumor that is likely recurrent\u002Fprogressive high- grade glioma as identified on preoperative MR imaging\n* Age ≥ 18 years old\n* Volumetric MRI within 1 month prior to surgery\n* Karnofsky performance status of 60 or higher\n* The participant (or legally acceptable representative if applicable) provides written informed consent for the trial.\n* Participants must be considered appropriate neurosurgical candidates with the following screening\u002Fbaseline laboratory values within 1 month prior to surgery:\n\n  * Absolute neutrophil count ≥ 1500\u002FµL\n  * Platelets ≥ 100 000\u002FµL\n  * International normalized ratio (INR) OR prothrombin time (PT) Activated partial thromboplastin time (aPTT) ≤1.5 × Upper limit of normal (ULN) unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants\n  * Urine or Serum Pregnancy Test = Negative (Not applicable to participants with bilateral oophorectomy and\u002For hysterectomy or to those participants who are postmenopausal).\n\nExclusion Criteria:\n\n* Severe co-morbidity that would confer excess risk of surgery as determined by the treating physician.\n* Any other major medical illnesses or psychiatric impairments that in the investigator's opinion will prevent administration or completion of protocol therapy.\n* Is pregnant\n* Coagulopathy or platelet dysfunction that increases the risk of intra and postoperative hemorrhage\n* Tumor location requiring DE placement\u002Fbiopsy in eloquent or critical region of the brain (e.g. primary motor and sensory cortices, speech and vision centers, thalamus, basal ganglia, cerebellum, brain stem) as deemed by the neurosurgeon designing the surgical plan",{"count":222,"type":21},10,[107],"The purpose of this study is to test the safety and feasibility of recording brain activity within and around high-grade glioma tumors at the time of surgery. A small biopsy will be taken at the sites of the recordings.",[226,131],"High Grade Glioma",[226,131,228,229],"Neural Recording","Electrical Activity",{"date":111,"type":36},{"date":232,"type":36},"2024-04-09",{"date":69,"type":21},{"name":42,"class":43},{"id":236,"slug":237,"hasResults":12,"nctId":238,"briefTitle":239,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":12,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":241,"targetDuration":4,"studyType":22,"phases":243,"briefSummary":244,"conditions":245,"keywords":247,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":253,"completionDateStruct":254,"leadSponsor":256,"locationsCount":71},"100634567","feasibility-and-acceptability-of-wearable-sensors-and-epros-in-early-phase-clinical-trials-100634567","NCT07541365","Feasibility and Acceptability of Wearable Sensors and ePROs in Early Phase Clinical Trials","Inclusion Criteria:\n\n* Age ≥18 years at the time of enrollment\n* Access to a mobile phone running iOS (X or more recent) or Android 14 (or more recent)\n* Ability to connect their mobile phone with their existing or provided smartwatch\n* Ability to read and understand English\n* Referred to the Novel Therapeutics Clinic and enrolled in an early-phase clinical trial\n* Ability to demonstrate the use of a mobile device and application for electronic patient-reported outcome (ePRO) completion\n* Willingness to wear an actigraphy device for 4 weeks, at least 12 hours per day over four weeks.\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Upper limb amputation, extensive tattoos, or lymphedema that may interfere with actigraphy data collection.",{"count":242,"type":21},30,[83],"Wearable sensors offer opportunities to improve the people's experiences with cancer treatment and to improve care delivery. This is a single-arm, prospective, unblinded pilot study designed to evaluate the feasibility and acceptability of wearable sensor-based monitoring and incorporating electronic patient-reported outcomes (ePROs) in Phase I oncology clinical trials. The study will enroll participants enrolled in early phase clinical trials at the Cleveland Clinic Novel Therapeutics Clinic and aims to establish the foundation for future, larger-scale prospective studies integrating digital health technologies into early-phase cancer clinical trials. Participants will be offered a smartwatch device compatible to their phone's operating system and be guided through the installation and use of the researchers' free study mobile application. Participants already owning compatible smartwatch devices may elect to use their own smartwatch for the study.",[246],"Cancer",[248,249,250],"Phase 1 Clinical Trials","Actigraphy","Wearable","2026-06-23",{"date":111,"type":36},{"date":67,"type":21},{"date":255,"type":21},"2027-01",{"name":42,"class":43},{"id":258,"slug":259,"hasResults":12,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":12,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":22,"phases":266,"briefSummary":267,"conditions":268,"keywords":270,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":274,"startDateStruct":275,"completionDateStruct":276,"leadSponsor":278,"locationsCount":71},"100612026","phase-2-memory-avoidance-whole-brain-radiotherapy-vs-hippocampal-avoidance-whole-brain-radiotherapy-athena-2-trial-100612026","NCT07248228","Memory Avoidance Whole Brain Radiotherapy vs Hippocampal Avoidance Whole Brain Radiotherapy (Athena 2 Trial)","A Randomized Phase 2 Trial of Memory Avoidance Whole Brain Radiotherapy Versus Hippocampal Avoidance Whole Brain Radiotherapy (Athena 2 Trial)","Inclusion Criteria:\n\n* Participants must have histologically, cytologically, or radiographically confirmed diagnosis of solid tumor with brain metastases\n* Age \\>18 years\n* Performance status: Karnofsky Performance Status (KPS) ≥ 70\n* Estimated life expectancy of at least 3 months\n* Participant must be considered a candidate for WBRT by the treating physician\n* Participant must be a primary English speaker and have the ability to understand and the willingness to sign an English written informed consent document\n* Participant has at least 10 brain metastases or is otherwise suitable for WBRT\n\nExclusion Criteria:\n\n* Prior whole brain radiation\n* Participant has Multiple Sclerosis, Alzheimer's, dementia, or mental disability\n* Pregnant or breastfeeding women are excluded from this study.\n* Participant is not able to receive an MRI\n* Participant has metastasis within avoidance neurocognitive substructures (hippocampus, amygdala, fornix, corpus callosum, pituitary, amygdala)",{"count":265,"type":21},90,[24],"Participants in this research study have cancer that has spread to their brain, called brain metastases. One treatment for this type of cancer is called whole brain radiotherapy that stays away from a specific neurocognitive substructure, called the hippocampus, combined with medication to preserve cognitive function. This study compares that approach to another approach of whole brain radiotherapy that stays away from additional structures that are thought to have a role in cognitive function. Researchers want to see if there is a difference in the preservation of cognitive function between these two approaches.",[269],"Brain Metastases",[271,272,273],"Whole brain radiotherapy","Memory-avoidance whole brain radiotherapy","Hippocampal-avoidance whole brain radiotherapy",{"date":111,"type":36},{"date":67,"type":21},{"date":277,"type":21},"2028-11",{"name":42,"class":43},{"id":280,"slug":281,"hasResults":12,"nctId":282,"briefTitle":283,"officialTitle":284,"acronym":4,"eligibilityCriteria":285,"healthyVolunteers":12,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":286,"targetDuration":4,"studyType":22,"phases":287,"briefSummary":288,"conditions":289,"keywords":292,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":296,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":71},"100609835","transanal-irrigation-for-the-management-of-early-low-anterior-resection-syndrome-lars-100609835","NCT07219745","Transanal Irrigation for the Management of Early Low Anterior Resection Syndrome (LARS)","Transanal Irrigation for the Management of Early Low Anterior Resection Syndrome (LARS): A Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n1. Adults (≥18 years-old) patients who underwent a LAR for any indication via open, laparoscopic, robotic, or transanal total mesorectal excision, with creation of a diverting loop ileostomy,\n2. have confirmed anastomotic healing demonstrated by flexible sigmoidoscopy and CT scan with rectally-administered water soluble contrast or gastrograffin enema,\n3. are planned for an ileostomy closure operation, and\n4. are in the first 12 months post-LAR operation\n\nExclusion Criteria:\n\n1. Inability to comprehend English or Spanish or provide informed consent (Note: after the English documents are approved, the study team plans to obtain a Spanish consent and study documents),\n2. ongoing chemotherapy or radiotherapy, and\n3. ongoing anastomotic complication.",{"count":5,"type":21},[83],"Transanal irrigation (TAI) has shown to improve fecal incontinence and increase quality of life in patients with low anterior resection syndrome (LARS). This trial is a small study being conducted to determine whether a larger trial is feasible. Investigators are also doing this research to see if TAI impacts quality of life and improves bowel function within the early post-operative period (1-12 months).\n\nThis treatment is designed for participants to have more control over their bowel movements and reduce the dependency on immediate access to the toilet.",[290,291],"Colorectal Cancer","Low Anterior Resection Syndrome",[293,294,291,295],"Transanal irrigation","Peristeen Transanal Irrigation System","LARS",{"date":111,"type":36},{"date":298,"type":21},"2026-10",{"date":300,"type":21},"2027-11",{"name":42,"class":43},{"id":303,"slug":304,"hasResults":12,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":308,"eligibilityCriteria":309,"healthyVolunteers":12,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":310,"targetDuration":4,"studyType":22,"phases":312,"briefSummary":313,"conditions":314,"keywords":317,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":321,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":71},"100601411","tongue-proactive-strengthening-exercise-program-following-partialhemi-glossectomy-and-reconstruction-100601411","NCT07110142","Tongue Proactive Strengthening Exercise Program Following Partial\u002FHemi Glossectomy and Reconstruction","Impact of Tongue Proactive Strengthening Exercise Program on Speech and Swallowing Outcomes Following Partial\u002FHemiglossectomy and Reconstruction","T-PROSE","Inclusion Criteria:\n\n1. ≥18 years of age\n2. No prior history of head and neck cancer\n3. No prior history of radiation\n4. Planned to undergo resection of ≤50% of the native tongue (partial\u002Fhemiglossectomy) with immediate reconstruction, including free flap reconstruction, and with or without neck dissection\n5. Sufficiently fluent in written English, French, Spanish or Simplified Chinese to complete the study outcomes questionnaires\n\nExclusion Criteria:\n\n1. Distant metastasis at enrollment\n2. Previously seen and treated by speech and language pathologist for dysphagia or dysarthria for non-head and neck cancer causes\n3. Prior head and neck radiation\n4. Requires mandibulectomy or \\>50% resection of native tongue",{"count":311,"type":21},40,[83],"This study is being done to determine whether adding a proactive tongue strengthening exercise program using a biofeedback device (the Tongueometer) improves speech and swallowing outcomes after surgery for tongue cancer. Patients who undergo partial or hemiglossectomy often experience difficulties with speech and swallowing, which can significantly impact their quality of life. While speech and swallow therapy is typically provided in response to problems, this study investigates whether introducing structured tongue strengthening exercises with biofeedback early-can lead to better long-term outcomes. This research will help establish whether this approach should become part of standard post-operative care.",[315,316],"Oral Cancer","Head and Neck Cancer",[318,319,320],"Speech-Language Pathology","Hemiglossectomy","Tongueometer",{"date":111,"type":36},{"date":323,"type":36},"2025-12-10",{"date":325,"type":21},"2029-06",{"name":42,"class":43},{"id":328,"slug":329,"hasResults":12,"nctId":330,"briefTitle":331,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":12,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":333,"targetDuration":4,"studyType":22,"phases":335,"briefSummary":336,"conditions":337,"keywords":341,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":71},"100611515","vitamin-d-effects-on-immune-microenvironment-of-nonmelanoma-skin-cancer-after-photodynamic-therapy-pdt-100611515","NCT07241585","Vitamin D Effects on Immune Microenvironment of Nonmelanoma Skin Cancer After Photodynamic Therapy (PDT)","Inclusion Criteria:\n\n* Must be an adult participant (\\> 18 yrs) who is scheduled to undergo Mohs surgery or ED\\&C within the Dermatologic Surgery unit of the Department of Dermatology, Cleveland Clinic.\n* Must have at least one BCC or SCC tumor eligible for removal by Mohs surgery.\n* The original tumor size prior to biopsy must be \\>1.0 cm (in the longest diameter).\n* Participants of any ethnic group are eligible for this trial.\n* Must provide informed consent to participate in the trial.\n* Participant must live in Ohio (Groups 2 \\& 3), because Research Pharmacy cannot ship the study drugs outside of the state.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding\n* Currently being treated for other cancers with medical or radiation therapy\n* Known hypersensitivity to 5-aminolevulinic acid\n* History of a photosensitivity disease, e.g., porphyria cutanea tarda",{"count":334,"type":21},54,[83],"This research study is for people who have been diagnosed with a nonmelanoma skin cancer (either basal cell carcinoma or squamous cell carcinoma) and are planning to receive either Mohs surgery or ED\\&C (electrodessication \\& curettage) as part of clinical care. The purpose of this study is to understand how photodynamic therapy (PDT) with or without Vitamin D can promote an immune response to skin cancer.\n\nFor this study, participants will be randomized (randomly assigned) and asked to take Vitamin D or placebo for 6 days and come to the clinic for a single PDT treatment 1-14 days prior to their surgery. At this visit, photographs of participant's skin cancer will be taken, and participants will undergo PDT treatment. The study team will also take photos on the day of Mohs surgery or ED\\&C. There will be up to two blood draws for research.\n\nIf participants do not want to come in for a PDT treatment prior to their Mohs surgery or ED\\&C, they will have the option to participate by only allowing the study team to collect data about their skin cancer and their tissue from Mohs surgery or ED\\&C.",[338,339,340],"Nonmelanoma Skin Cancer","Basal Cell Carcinoma","Squamous Cell Carcinoma",[342,343,344,345,346,347],"Mohs surgery","Electrodessication & curettage","ED&C","Photodynamic therapy","PDT","Vitamin D","2026-06-17",{"date":350,"type":36},"2026-06-18",{"date":352,"type":36},"2026-02-25",{"date":354,"type":21},"2027-08",{"name":42,"class":43},{"id":357,"slug":358,"hasResults":12,"nctId":359,"briefTitle":360,"officialTitle":361,"acronym":4,"eligibilityCriteria":362,"healthyVolunteers":12,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":363,"targetDuration":4,"studyType":22,"phases":365,"briefSummary":366,"conditions":367,"keywords":369,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":372,"startDateStruct":373,"completionDateStruct":375,"leadSponsor":376,"locationsCount":71},"100485925","phase-2-methimazole-in-patients-with-progressive-glioblastoma-100485925","NCT05607407","Methimazole in Patients With Progressive Glioblastoma","Targeting Transsulfuration Via Suppression of Thyroid Hormone Signaling in Progressive Glioblastoma: Phase 2 and Pharmacodynamic Trial of Methimazole in Patients With Progressive Glioblastoma","Inclusion Criteria:\n\n* Subjects must have histologically or cytologically confirmed WHO grade 4 glioma (including tumors with molecularly defined grade 4 astrocytoma) for which a clinically indicated tumor resection is planned.\n* Subjects must not have received methimazole for this disease.\n* Age is greater than or equal to 18 years of age\n* Performance status: Karnofsky Performance status ≥ 70%\n* Subjects must have adequate organ function and laboratory parameters within 21 days of study entry as defined below: Hemoglobin ≥ 8 g\u002Fdl, Absolute neutrophil count ≥ 1,200\u002FmcL, Platelet count ≥ 75,000\u002FmcL, Total bilirubin \\\u003C 1.5 x institutional upper limit of normal (ULN), AST (SGOT) ≤ 3 X institutional ULN, ALT (SGPT) ≤ 3 X institutional ULN, Calculated creatinine clearance \\> 50 mL\u002Fmin, Prothrombin time\u002Finternational normalized ratio (PT\u002FINR) \\\u003C1.4 for patients not on warfarin, Patients on full-dose anticoagulants (e.g., warfarin or LMW heparin) must meet both of the following criteria: No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices), In-range INR (between 2 and 3) on a stable dose of oral anticoagulant or on a stable dose of low molecular weight heparin\n* Subjects must have normal thyroid function within 21 days of study entry as defined below: ≤ 3 X institutional ULN\n* Women of childbearing potential must have a negative pregnancy test within 21 days of study entry. Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and through 30 days after the last dose of study drug. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. Men of reproductive potential treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and through 30 days after the last dose of study drug.\n* Patients must be able to swallow whole tablets.\n* Patients must have the following minimum intervals from prior treatments: surgery - 4 weeks, nitrosoureas - 6 weeks, cytotoxic chemotherapy - standard intervals depending on the most recent regimen. i.e., for temozolomide 5 of 28, 23 days after most recent temozolomide; for temozolomide 21 of 28 days, 7 days after most recent dose; etoposide 14 of 21 days, 7 days after last dose. For drugs not listed, the research nurse, treating investigator, and principal investigator will determine the appropriate interval, Investigational therapy or non-cytotoxic therapy - 2 weeks, For bevacizumab - 4 weeks from anticipated date of protocol surgery\n* Patients positive for human immunodeficiency virus (HIV) are allowed on study (note: HIV testing is not required), but HIV-positive patients must have: An undetectable viral load within 6 months of registration, A stable regimen of highly active anti-retroviral therapy (HAART), No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\n* For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.\n* For patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load\n* Patient must be deemed by investigator to be a candidate for post-operative chemotherapy.\n* Subjects must have the ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Prior treatment toxicities not resolved to ≤ Grade 1 according to NCI CTCAE Version 5.0 except alopecia and neuropathy.\n* Subjects receiving any other investigational agents.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to methimazole.\n* Subjects with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Other prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen are excluded. Otherwise, patients with prior or concurrent malignancy are eligible.\n* Significant chronic gastrointestinal disorder with diarrhea as a major symptom (e.g., Crohn's disease, malabsorption, or Grade ≥2 (National Cancer Institute \\[NCI\\] Common Terminology Criteria for Adverse Events Version 5.0 \\[CTCAE v.5.0\\] diarrhea of any etiology at screening).\n* Pregnant or breastfeeding.\n* Known history of hyperthyroidism or hypothyroidism\n* Unable or unwilling to swallow tablets.\n* Evidence of significant medical illness, abnormal laboratory finding, or psychiatric illness\u002Fsocial situations that would, in the Investigator's judgment, make the patient inappropriate for this study.",{"count":364,"type":21},19,[24],"The purpose of this study is to test the effectiveness, safety, and tolerability of a drug called Methimazole. The investigational drug, Methimazole is not FDA approved for brain tumors, but it is used to treat thyroid illnesses. Different doses of Methimazole will be given to several study participants with glioblastoma. The first several study participants will receive the lowest dose. If the drug does not cause serious side effects, it will be given to other study participants at a higher dose. The doses will continue to increase for every group of study participants until the side effects occur that require the dose to be lowered. The procedures in this study are research blood draws, physical exams, collection of medical history, MRI scans, and study drug administration.",[131,368],"Glioma",[370,371],"Transsulfuration","Methimazole",{"date":350,"type":36},{"date":374,"type":36},"2023-01-30",{"date":117,"type":21},{"name":42,"class":43},{"id":378,"slug":379,"hasResults":12,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":4,"eligibilityCriteria":383,"healthyVolunteers":12,"sex":51,"minAge":53,"maxAge":384,"enrollmentInfo":385,"targetDuration":4,"studyType":22,"phases":386,"briefSummary":387,"conditions":388,"keywords":395,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":400,"completionDateStruct":401,"leadSponsor":403,"locationsCount":71},"100641453","transcriptional-pathways-of-surgical-pain-modulated-by-music-therapy-exposure-transpose-100641453","NCT07653594","TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE)","TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE): A Single Arm Pilot Study","Inclusion Criteria:\n\n* Age 50 to 80\n* Able to speak and understand English\n* Scheduled to undergo a surgery meeting the following criteria: (1) traditional open surgery (not laparoscopic or robotic) via laparotomy (midline or subcostal incisions), (2) length of surgery \\>3 hours, and (3) curative-intent surgical resection of a cancer in the stomach, pancreas, bile ducts, liver, or peritoneal surfaces\n* Participant reports pain intensity of 4\u002F10 or above to study staff on day 1 post-surgery or any other day post-surgery through discharge\n\nExclusion Criteria:\n\n* Significant visual impairment that has not been corrected\n* Significant hearing impairment that has not been corrected\n* Significant cognitive impairment that would prevent participant from participating in the study","80 Years",{"count":151,"type":21},[83],"Participants may take part in this study if they are scheduled to undergo a surgery that meets the following: (1) traditional open surgery via laparotomy, (2) length of surgery \\>3 hours, and (3) curative-intent surgical resection of a cancer in the stomach, pancreas, bile ducts, liver, or peritoneal surfaces. The purpose of this study is (1) to evaluate the feasibility of collecting blood samples prior to surgery, post-surgery and pre- music-assisted relaxation and imagery (MARI) intervention, and immediately post-MARI intervention and (2) to identify gene expression changes associated with MARI and explore their relationship with immediate changes in pain intensity. Participants will be in this study for the duration of their hospital admission for surgery.",[389,390,391,392,393,394],"Surgery","Stomach Cancer","Pancreas Cancer","Bile Duct Cancer","Liver Cancer","Peritoneal Cancer",[396,397],"Music therapy","Music-assisted relaxation and imagery","2026-06-15",{"date":348,"type":36},{"date":255,"type":21},{"date":402,"type":21},"2027-12",{"name":42,"class":43},{"id":405,"slug":406,"hasResults":12,"nctId":407,"briefTitle":408,"officialTitle":408,"acronym":4,"eligibilityCriteria":409,"healthyVolunteers":12,"sex":51,"minAge":410,"maxAge":384,"enrollmentInfo":411,"targetDuration":4,"studyType":22,"phases":413,"briefSummary":414,"conditions":415,"keywords":417,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":421,"startDateStruct":423,"completionDateStruct":425,"leadSponsor":427,"locationsCount":71},"100476266","unintentional-weight-loss-and-cancer-a-prospective-trial-of-patient-centered-weight-tracking-combined-with-grail-galleri-testing-to-improve-early-detection-100476266","NCT05481697","Unintentional Weight Loss and Cancer: A Prospective Trial of Patient-centered Weight Tracking Combined With GRAIL Galleri Testing to Improve Early Detection","Inclusion Criteria:\n\n* Age range: from 40 to 80 years\n* Access to a device (cellphone, computer, tablet) that is compatible with the Fitbit Aria Air smart scale utilized in this study\n* Willing to comply with all study procedures and be available for the duration of the study\n* Subjects must be mentally competent and must have the ability to understand and the willingness to sign a written informed consent document\n* Subjects must speak English to maximize chance of understanding the trial rational and study procedures\n\nExclusion Criteria:\n\n* Active cancer diagnosis - current diagnosis, currently undergoing cancer treatment, or concluded cancer treatments within 3 years\n* Actively trying to lose weight with medications or bariatric surgery\n* Pregnant","40 Years",{"count":412,"type":21},1000,[83],"Unintentional weight loss (UWL) is commonly associated with a wide variety of diseases and there is still no valid diagnostic pathway for evaluating UWL. When detecting UWL coupled with GRAIL Galleri testing, (an investigational pan-cancer early detection test), it is thought that there is a greater positive predictive value in detecting malignancies. This study aims to test the potential synergistic effects of UWL detection and GRAIL usage to detect malignancy at an even earlier rate. UWL will be measured using weekly weight tracking.",[416],"Unintended Weight Loss",[418,416,419],"GRAIL Galleri","UWL","2026-06-11",{"date":422,"type":36},"2026-06-12",{"date":424,"type":36},"2023-05-05",{"date":426,"type":21},"2027-01-01",{"name":42,"class":43},{"id":429,"slug":430,"hasResults":12,"nctId":431,"briefTitle":432,"officialTitle":433,"acronym":4,"eligibilityCriteria":434,"healthyVolunteers":12,"sex":51,"minAge":173,"maxAge":4,"enrollmentInfo":435,"targetDuration":4,"studyType":22,"phases":436,"briefSummary":437,"conditions":438,"keywords":441,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":445,"startDateStruct":447,"completionDateStruct":448,"leadSponsor":450,"locationsCount":71},"100538427","phase-2-partial-cystectomy--extended-pelvic-lymph-node-dissection-with-soc-perioperative-systemic-therapy-100538427","NCT06290687","Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy","Phase II Trial on the Safety and Efficacy of Partial Cystectomy and Extended Pelvic Lymph Node Dissection With Standard of Care Perioperative Systemic Therapy in the Management of Muscle-Invasive Bladder Cancer (PRESERVE Trial)","Inclusion Criteria:\n\n* Subjects must have histologically confirmed urothelial carcinoma of the bladder, clinical stage T2-3N0M0. Micropapillary, glandular, squamous, and sarcomatoid histologic variants of urothelial carcinoma are allowed.\n* Subjects must have unifocal or limited multifocal disease amenable to complete surgical resection with partial cystectomy, as judged by the treating urologic oncologist.\n* Age \\>18 years. Because of the rarity of this disease and limited data on treatment efficacy in subjects 18 years of age, children are excluded from this study.\n* Performance status - Karnofsky Performance Status ≥70 or Eastern Cooperative Oncology Group (ECOG) performance status Grade 0 or 1.\n* Subjects must have normal organ and marrow function as defined below:\n\n  * Total bilirubin within normal limits\n  * AST (SGOT) ≤ 2.5 X institutional upper limit of normal\n  * ALT (SGPT) ≤ 2.5 X institutional upper limit of normal\n  * Bone marrow:\n\n    * Absolute neutrophil count (ANC) ≥ 1,500\u002Fmm3\n    * Platelet count ≥ 80,000\u002Fmm3, Hemoglobin ≥ 9.0 g\u002FdL\n* Subjects must have the ability to understand and the willingness to sign a written informed consent document.\n* Subjects must have tumor less than or equal to 5 cm in largest dimension as assessed radiographically.\n* Treatment naive for MIBC.\n\nExclusion Criteria:\n\n* Presence of hydronephrosis.\n* Presence of multifocal disease that is not amenable to complete resection with partial cystectomy.\n* Presence of distant carcinoma in situ.\n* Presence of clinical N+ or M+ disease.\n* Presence of cT4+ disease.\n* Non-urothelial histology.\n* Concurrent upper tract (ureter or renal pelvis) or urethral urothelial carcinoma.\n* Subjects who are not surgical candidates due to competing medical comorbidities or who refuse surgical treatment.\n* Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (eg, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.",{"count":311,"type":21},[24],"The goal of this clinical trial is to determine if a partial cystectomy with extended pelvic lymph node removal will be effective at treating Muscle-Invasive Bladder Cancer instead of a complete cystectomy with extended pelvic lymph node removal. This clinical trial aims to determine the safety and oncologic efficacy of the intervention, and to examine patient-reported quality of life outcomes in participants. Participants will receive the standard pre-surgery treatment for approximately 4 to 6 weeks. After the pre-surgery treatment is completed, participants will undergo a partial cystectomy with extended pelvic lymph node dissection. After surgery, participants will receive adjuvant systemic therapy.",[439,440],"Malignant Neoplasm of Bladder","Muscle Invasive Bladder Carcinoma",[442,443],"Partial cystectomy","Pelvic Lymph Node Dissection","2026-06-04",{"date":446,"type":36},"2026-06-05",{"date":67,"type":21},{"date":449,"type":21},"2027-12-29",{"name":42,"class":43},{"id":452,"slug":453,"hasResults":12,"nctId":454,"briefTitle":455,"officialTitle":456,"acronym":457,"eligibilityCriteria":458,"healthyVolunteers":12,"sex":51,"minAge":18,"maxAge":459,"enrollmentInfo":460,"targetDuration":4,"studyType":22,"phases":461,"briefSummary":462,"conditions":463,"keywords":467,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":471,"startDateStruct":472,"completionDateStruct":473,"leadSponsor":475,"locationsCount":71},"100522604","phase-2-intestinal--multivisceral-transplantation-for-unresectable-mucinous-carcinoma-peritonei-transcape-100522604","NCT06084780","Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)","Prospective Case Series of Intestinal and Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)","TRANSCAPE","Inclusion Criteria:\n\n* Subjects must have histologically confirmed pseudomyxoma peritonei (PMP)\n\n  * Both low-grade mucinous carcinoma peritonei (LMCP) or high-grade mucinous carcinoma (HMCP), with or without signet ring cells as well as primary or recurrent disease, will be eligible.\n* PMP disease does not have any extra-abdominal metastases, with the exception of pulmonary involvement (nodal, parenchymal, and pleural).\n* PMP disease is extensive and not amenable to operative management, with or without liver, pancreas, stomach, or abdominal wall involvement.\n\n  * Definition of Non-Resectable Disease-\n\n    * Non-resectable PMP disease will be defined as the presence of at least one of the following conditions:\n\n      * 1\\) Extensive small bowel serosa involvement, where it is not possible to preserve at least 1.5-2 m of small bowel\n      * 2\\) Extensive infiltration of the pancreatic surface\n      * 3\\) Mesenteric involvement causing retraction\n      * 4\\) Need for complete gastric resection\n      * 5\\) Urete1ic obstruction\n      * 6\\) Liver disease with no chance to achieve R0 resection with liver remnant volume \\> 30%\n      * 7\\) Recurrent disease not amenable to further resection\n* Subjects do not have any other available curative treatment options.\n\n  * Subjects can have previous abdominal operations, including CRS+HIPEC.\n* Age ≥ 18 and ≤ 75.\n\n  * Pediatric participants were excluded as PMP is a disease that affects adults. Participants \\> 75 years of age are excluded as they are beyond the commonly accepted transplantability criteria.\n* Performance status ECOG ≤ 1.\n* Subjects must have the ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Subjects with peritoneal carcinomatous originating from an etiology other than PMP.\n* Subjects receiving any other investigational agents.\n* Subjects with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would either put participation at risk because of participation in the study, may influence the result of the study, or limit compliance with study requirements.\n* Pregnant women are excluded from this study because an intestinal transplant is a procedure that is not compatible with a viable pregnancy.\n* Subjects who are HIV-positive may be included in the study. HIV testing is required for the study as adequate HIV treatment is required prior to intestinal transplant due to the increased risk of infection following transplantation and treatment with immunosuppressive agents.","75 Years",{"count":151,"type":21},[24],"The goal of this prospective phase 2 study is to assess the efficacy and safety of intestinal or multivisceral transplantation for participants with PMP not amenable to other curative-intent treatments. Participants will undergo intestinal\u002Fmultivisceral transplantation. Participants will be followed for 12 months to assess efficacy and safety.",[464,465,466],"Secondary Malignant Neoplasm of Retroperitoneum","Secondary Malignant Neoplasm of Peritoneum","Pseudomyxoma Peritonei",[468,469,466,470,457],"Intestinal Transplantation","Multivisceral Transplantation","Unresectable Mucinous Carcinoma Peritonei",{"date":446,"type":36},{"date":94,"type":21},{"date":474,"type":21},"2026-12-31",{"name":42,"class":43},{"id":477,"slug":478,"hasResults":12,"nctId":479,"briefTitle":480,"officialTitle":481,"acronym":4,"eligibilityCriteria":482,"healthyVolunteers":12,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":483,"targetDuration":4,"studyType":22,"phases":485,"briefSummary":486,"conditions":487,"keywords":489,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":494,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":498,"locationsCount":71},"100455424","phase-1-disulfiram-with-copper-gluconate-and-liposomal-doxorubicin-in-treatment-refractory-sarcomas-100455424","NCT05210374","Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas","Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Patients With Treatment-Refractory Sarcomas","Inclusion Criteria:\n\n* Must have histologically confirmed relapsed or refractory sarcoma.\n* Must have measurable disease by RECIST criteria at study enrollment\n* Performance status of Karnofsky\u002FLansky ≥50%\n* Must have normal organ and marrow function as defined below:\n\n  * Absolute neutrophil count ≥1,000\u002FmcL\n  * Platelet count ≥ 100,000\u002FmcL\n  * Total bilirubin within normal institutional limits\n  * AST (SGOT) ≤ 2.5 X institutional upper limit of normal\n  * ALT (SGPT) ≤ 2.5 X institutional upper limit of normal\n  * Serum Creatinine ≤1.5X institutional limit of normal\n* Must be able to swallow pills or consume the contents of the DSF and Capsules sprinkled on food.\n* Participants, or parent\u002Fguardians for participants \\\u003C18 years old (yo), must have the ability to understand and the willingness to sign a written informed consent document.\n* Must abstain from alcohol during study.\n* Prior treatment toxicities must have stabilized or resolved to ≤ Grade 1 according to NCI CTCAE Version 5.0 except alopecia, neuropathy and hematologic criteria (must meet normal organ and marrow function criteria above).\n* Participants ≥18yo must agree to pre-and post-treatment core needle tumor biopsies. For participants \\\u003C18yo biopsies are optional. Biopsies will not be performed if deemed unsafe by interventional radiologists that will be performing the procedure and is not part of the study team to avoid bias.\n* Must abstain from sexual intercourse or used appropriate, highly-effective birth control measures.\n\nExclusion Criteria:\n\n* Has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy\n* Has a history of allergy or hypersensitivity to any of the study drugs, their pharmaceutical class or any of their excipients. The participant exhibits any of the events outlined in the Contraindications or Special Warnings and Precautions sections of Liposomal Doxorubicin Prescribing Information package inserts or on the Investigator's Brochure for DSF\u002FCu.\n* Has a concomitant serious medical or psychiatric illness that, in the opinion of the investigator, could compromise the participant's safety or the study data integrity.\n* Is currently enrolled in any other clinical protocol or investigational trial involving administration of antineoplastic compounds for the treatment of their sarcoma.\n* Is unwilling or unable to comply with study procedures.\n* Know condition preventing safe administration of copper such as a copper allergy or Wilson's Disease.\n* Investigator feels participation in this study would be harmful or of no benefit to the potential participant",{"count":484,"type":21},24,[107],"The purpose of this study is to test the safety of combining the disulfiram (DSF) and copper gluconate (Cu) to liposomal doxorubicin to treat patients with sarcomas that recurred or did not respond to initial treatment.",[488],"Relapsed Sarcomas",[490,491,492,493],"Sarcoma,","osteosarcoma","rhabdomyosarcoma","Ewing sarcoma",{"date":446,"type":36},{"date":496,"type":36},"2023-03-09",{"date":474,"type":21},{"name":42,"class":43},{"id":500,"slug":501,"hasResults":12,"nctId":502,"briefTitle":503,"officialTitle":504,"acronym":4,"eligibilityCriteria":505,"healthyVolunteers":12,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":506,"targetDuration":4,"studyType":22,"phases":507,"briefSummary":509,"conditions":510,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":512,"startDateStruct":513,"completionDateStruct":515,"leadSponsor":516,"locationsCount":71},"100388020","early-phase-1-study-of-nicotinamide-riboside-supplementation-in-allogeneic-hematopoietic-cell-transplantation-100388020","NCT04332341","Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation","A Pilot Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation","Inclusion Criteria:\n\n* All disease indications for allogeneic hematopoietic cell transplantation except for myelofibrosis.\n* Subject must meet program eligibility criteria\\* for myeloablative conditioning alloHCT and plan to undergo myeloablative conditioning.\n* HLA-identical related donor or unrelated human donor source with bone marrow graft.\n* Subjects must provide a written informed consent.\n\nExclusion Criteria:\n\n* History of allergy or intolerance to NR precursor compounds, including niacin or nicotinamide\n* Pregnant or breastfeeding women are excluded from this study since allogeneic HCT is a strict contraindication.\n* Subjects with uncontrolled intercurrent illness or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.",{"count":151,"type":21},[508],"EARLY_PHASE1","The purpose of this study is to find a safe and tolerable way to improve engraftment after transplant. Research studies have shown that adding nicotinamide riboside to donor cells has the potential to increase blood stem cell numbers and potentially decrease the time to engraftment. Also, nicotinamide riboside, TRU NIAGEN (the study drug) is a type of vitamin B supplement that the general public can get without a prescription and is well tolerated.",[511],"Allogeneic Hematopoietic Cell Transplantation",{"date":446,"type":36},{"date":514,"type":36},"2020-05-19",{"date":117,"type":21},{"name":42,"class":43},{"id":518,"slug":519,"hasResults":12,"nctId":520,"briefTitle":521,"officialTitle":521,"acronym":4,"eligibilityCriteria":522,"healthyVolunteers":12,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":523,"targetDuration":4,"studyType":22,"phases":525,"briefSummary":526,"conditions":527,"keywords":530,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":535,"startDateStruct":536,"completionDateStruct":538,"leadSponsor":539,"locationsCount":71},"100379287","phase-2-single--vs-two-fraction-spine-stereotactic-radiosurgery-for-the-treatment-of-vertebral-metastases-100379287","NCT04218617","Single- vs. Two-Fraction Spine Stereotactic Radiosurgery for the Treatment of Vertebral Metastases","Inclusion Criteria:\n\n* Karnofsky Performance Status (KPS) ≥ 70\n* RPA class 1 (KPS \\>70 AND controlled systemic disease) or RPA Class 2 (KPS \\>70, uncontrolled systemic disease OR KPS ≤70, age ≥54, no visceral metastases)44 (see Appendix II)\n* Vertebral metastases from C3 to L5 based on bone scan, CT, PET, or MRI.\n* Vertebral metastases must be (1) solitary, (2) at two contiguous levels, or (3) a maximum of three separate sites, with a maximum of two contiguous levels.\n* Radioresistant metastases are permitted (including sarcomas, melanomas, and renal cell carcinomas).\n* Patients with epidural disease are permitted so long as there is no cord compression.\n* Paraspinal extension is permitted, so long as the paraspinal component is ≤5 cm\n* Multiple small metastatic lesions (\\\u003C20% vertebral body involvement) of no clinical correlate are permitted, and not included in the irradiated segments as per RTOG 0631\n* History and physical within four weeks of registration.\n* Negative pregnancy test within four weeks of registration for women of childbearing potential.\n* Diagnostic spine MRI with and without contrast within four weeks of registration\n* Neurological exam within four weeks of registration to rule out rapid neurological decline. Mild to moderate neurological deficits are acceptable, as long as distance between lesion and spinal cord is ≥3 mm\n* Patients may have prior EBRT at the index site.\n* Informed consent of the participant.\n\nExclusion Criteria:\n\n* Lesions at C1-2 or S1-Coccyx.\n* Hematologic malignancies including lymphoma and myeloma.\n* Multiple primary cancers.\n* Primary neoplasms of the spine\n* Prior corpectomy, kyphoplasty\u002Fvertebroplasty, or instrumentation at the site of planned sSRS.\n* Spinal cord compression.\n* Paraspinal mass \\>5 cm.\n* Patients with rapid neurologic decline.\n* Bony retropulsion resulting in neurologic deficit.\n* Patients with contraindications to MRI.\n* Patients allergic to intravenous contrast for MRI or CT.\n* Patients with emergent spinal cord compression.\n* Patients with mechanical instability of the spine.\n* Patients with active connective tissue disease.\n* Patients who previously underwent sSRS to the vertebrae of interest.\n* Patients with diffuse or multilevel metastatic spinal disease with \\>20% involvement of vertebral bodies, defined as involvement of \\>5 vertebral levels.\n* Inability to participate in study activities due to physical or mental limitations.\n* Inability or unwillingness to return for all required follow-up visits and imaging.\n* Inability to deliver sSRS, either 18 Gy in one fraction, or 24 Gy in two fractions.",{"count":524,"type":21},130,[24],"Spine radiosurgery (SRS) utilizes advanced treatment planning with focused x-rays to deliver one to four high dose treatments to the spine to help relieve pain and\u002For neurologic symptoms. Spine SRS uses special equipment to position the participant and guide the focused beams toward the area to be treated and away from normal tissue.\n\nOne of the side effects of spine SRS is the development of vertebral compression fractures, many of which are not painful. The goal of this study is to compare the effects, good and\u002For bad, of spine SRS given in 1 or 2 treatments. Our main goal is to find out which approach will reduce the chances of developing vertebral compression fractures.",[528,529],"Spine Metastases","Spine Stereotactic Radiosurgery (sSRS)",[531,532,533,534],"C79.40","C79.49","C79.51","C79.52",{"date":446,"type":36},{"date":537,"type":36},"2020-02-07",{"date":298,"type":21},{"name":42,"class":43},{"id":541,"slug":542,"hasResults":12,"nctId":543,"briefTitle":544,"officialTitle":545,"acronym":4,"eligibilityCriteria":546,"healthyVolunteers":12,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":547,"targetDuration":4,"studyType":22,"phases":548,"briefSummary":549,"conditions":550,"keywords":553,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":556,"startDateStruct":557,"completionDateStruct":559,"leadSponsor":560,"locationsCount":71},"100609814","scrambler-therapy-for-chemotherapy-induced-peripheral-neuropathy-100609814","NCT07219472","Scrambler Therapy for Chemotherapy-Induced Peripheral Neuropathy","A Randomized, Single-Blind, Sham-Controlled Study of Scrambler Therapy for Chemotherapy-Induced Peripheral Neuropathy","Inclusion Criteria:\n\n* Adults with CIPN-related pain for at least three months duration, and for which the participant wants intervention\n* At least three months from the last dose of neurotoxic cancer-directed drug\n* No plan (at the time of study enrollment) for additional neurotoxic cancer-directed therapies for at least five months after trial enrollment\n* Pain rated ≥ four out of 10 in severity (0-10 pain scale) during the seven days prior to enrollment\n* \\> six-month life expectancy\n* Able to complete questionnaires by themselves or with assistance\n* Able to provide informed written consent\n* ECOG Performance Status score ≥ two\n\nExclusion Criteria:\n\n* Pregnant or nursing\n* An operational implanted drug delivery system, implanted electronic medical device, life supporting medical device, and\u002For medical monitoring device\n* History of myocardial infarction or ischemic heart disease within six months of trial enrollment\n* History of epilepsy, brain damage resulting in seizure activity, or use of anticonvulsants for seizure\n* Skin conditions such as open sores that will prevent proper application of electrodes\n* Unwillingness or inability to wean and discontinue gabapentin or pregabalin prior to the start of ST\n* History of symptomatic peripheral neuropathy prior to receiving neurotoxic chemotherapy\n* Prior treatment with Scrambler Therapy",{"count":265,"type":21},[83],"This research study is for people who have a condition called chemotherapy-induced peripheral neuropathy (CIPN). This condition develops as a result of receiving medication(s) to treat cancer, particularly chemotherapy. CIPN is characterized by pain, numbness, tingling or burning sensations, typically in the hands and feet of people. These symptoms can lead to physical suffering, limited ability to perform daily activities, and low quality of life. One of the ways to treat CIPN is using a device called Scrambler Therapy. Scrambler Therapy was approved by the Food and Drug Administration (FDA) in 2009 as a treatment for CIPN. The treatment involves electrical signals passing through wires attached to parts of the body via adhesive tabs near where symptoms of CIPN are experienced. A standard treatment course consists of 10 daily sessions lasting about one hour each. The purpose of this study is to determine the effect of a 10-day course of Scrambler Therapy on symptoms of chemotherapy-induced peripheral neuropathy, day-to-day activities, overall quality of life, and use of pain medications. Participants will be randomly assigned to one of two groups. One group will receive Scrambler Therapy. The other group will not receive it. Participants will not know which group they were in until after treatment has completed. Participants in the group who did not receive Scrambler Therapy will have the opportunity to receive it after one month. Participants will be in this research study about 12 to 14 months.",[551,552],"Chemotherapy-induced Peripheral Neuropathy","CIPN - Chemotherapy-Induced Peripheral Neuropathy",[554],"Scrambler therapy","2026-06-03",{"date":444,"type":36},{"date":558,"type":36},"2026-03-27",{"date":402,"type":21},{"name":42,"class":43},{"id":562,"slug":563,"hasResults":12,"nctId":564,"briefTitle":565,"officialTitle":565,"acronym":4,"eligibilityCriteria":566,"healthyVolunteers":12,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":567,"targetDuration":4,"studyType":22,"phases":568,"briefSummary":569,"conditions":570,"keywords":573,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":575,"startDateStruct":576,"completionDateStruct":578,"leadSponsor":579,"locationsCount":71},"100602877","musculoskeletal-cancers-remote-monitoring-and-care-100602877","NCT07129226","Musculoskeletal Cancers Remote Monitoring and Care","Inclusion Criteria:\n\n* primary sarcoma or metastatic bone disease of the lower extremities or pelvis.\n* undergoing evaluation for (or have recently undergone) non-surgical or surgical intervention.\n* recent history of home ambulation.\n\nExclusion Criteria:\n\n* under 18 years of age at the time of study enrolment\n* inability to comprehend consent form and give informed consent\n* no access to a smartphone (iOS or Android) to interface with watch application\n* tattoos located on the skin of the wrist or forearm where the watch will be placed or other skin conditions preventing adequate sensor function\n* amputation or other disease of the arm or skin that prevents wear of a smart-watch device\n* inability to tolerate watch for at least 12 hours per day on at least 80% of days in a four-week period",{"count":5,"type":21},[83],"This study aims to evaluate how walking stability and the ability to perform daily activities change during cancer treatment, and whether a smartwatch can detect these changes. The goal is to develop proactive, personalized tools that automatically monitor treatment response and predict potential complications. To support future implementation, the study will assess the feasibility of wearing a smartwatch for at least 12 hours per day, using a mobile application, and completing weekly questionnaires among patients with primary osteosarcoma or metastatic bone disease.",[571,572],"Osteosarcoma","Metastatic Bone Disease",[574],"prophylactic surgery",{"date":444,"type":36},{"date":577,"type":36},"2026-02-11",{"date":94,"type":21},{"name":42,"class":43},{"id":581,"slug":582,"hasResults":12,"nctId":583,"briefTitle":584,"officialTitle":585,"acronym":4,"eligibilityCriteria":586,"healthyVolunteers":12,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":587,"targetDuration":4,"studyType":22,"phases":588,"briefSummary":589,"conditions":590,"keywords":593,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":596,"startDateStruct":597,"completionDateStruct":599,"leadSponsor":601,"locationsCount":71},"100564291","phase-2-antibiotic-treatment-effects-on-intratumoral-bacteria-modulation-in-surgical-patients-with-oral-cancer-100564291","NCT06627270","Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral Cancer","A Phase II Single-arm Cohort Study Establishing the Effect of Antibiotic Treatment on Intratumoral Bacteria in Surgical Patients With Oral Cancer","Inclusion Criteria:\n\n* Pathologically confirmed squamous cell carcinoma of the oral cavity\n* Must have planned surgery for curative intent\n* Participants ≥ 18 years of age\n* Participants must have the ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Known allergy to metronidazole and\u002For chlorhexidine\n* Severe liver or kidney disease as determined by history of laboratory tests\n* Participants actively drinking alcohol (unable to abstain for the 10 day antibiotic period)\n* Recurrent oral cancer after prior radiation or chemoradiation\n* Participants with unresectable oral cancer\n* Participants unable to tolerate oral rinse or unable to have metronidazole administered by mouth or by feeding tube\n* Participants currently or have taken other antibiotics within the prior 30 days\n* Participant is pregnant",{"count":242,"type":21},[24],"The goal of this phase II single arm clinical study is to evaluate the effect of antibiotics (metronidazole) and oral chlorhexidine (CHX) in reducing the bacteria load within tumors of patients undergoing surgery for oral cancer.",[591,315,316,592],"Oral Squamous Cell Carcinoma","Head and Neck Carcinoma",[594,595],"Metronidazole","Chlorhexidine",{"date":444,"type":36},{"date":598,"type":36},"2025-03-11",{"date":600,"type":21},"2027-10-01",{"name":42,"class":43},""]